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Edited by Richard MaraisAbstract Cadmium is a toxic metal that initiates both mito-
genic responses and cell death. We show that Cd2+ increases
phosphorylation and activity of Ca2+/calmodulin-dependent pro-
tein kinase II (CaMK-II) in mesangial cells, in a concentration-
dependent manner. Activation is biphasic with peaks at 1–5 min
and 4–6 h. Cadmium also activates Erk, but this appears to be
independent of CaMK-II. At 10–20 lM, Cd2+ initiates apoptosis
in 25–55% of mesangial cells by 6 h. Inhibition of CaMK-II, but
not of Erk, suppresses Cd2+-induced apoptosis. We conclude that
activation of CaMK-II by Cd2+ contributes to apoptotic cell
death, independent of Erk activation.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cadmium is an environmentally and occupationally impor-
tant toxic metal with a long biological half-life. It acts as a can-
cer promoter through mitogenic eﬀects on gene expression
(reviewed in [1]) and produces malignant tumors in experimen-
tal animals [2–5]. Cadmium is both pro- and anti-apoptotic in
circumstances that probably depend on both cell type and
duration and conditions of treatment. Thus it has been shown
to induce apoptosis in T lymphocytes [6], LLC-PK1 cells [7],
canine proximal tubules [8], and rat testicular tissue [9]. It
induces apoptosis by both caspase-dependent [10–12] and
caspase-independent [13] pathways. However, Cd2+ has also
been reported to block apoptosis induced by a variety of
agents, e.g., in CHO cells where the eﬀect was attributed to
the inhibition of caspase-3 [14]. We recently demonstrated
inhibition by Cd2+ of both intrinsic and extrinsic apoptotic
pathways in mesangial cells following initiation by camptothe-
cin and TNF-a, respectively [15].
Three major mitogen-activated protein kinase (MAPK)
pathways occur in mammalian cells, involving Erk, Jun kinase
(Jnk) and p38 [16]. In general, Erk is activated by growth fac-
tor receptors and stimulates cell proliferation, whereas Jnk andAbbreviations: CaMK, Ca2+/calmodulin-dependent kinase; MAPK,
mitogen-activated protein kinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; PI, propidium iodide
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Cadmium is a known regulator of each pathway [19–21], albeit
with diﬀerential eﬀects in diﬀerent cell types. All three MAPK
pathways are activated by Cd2+ in mesangial cells ([22,23] and
data not shown). In addition to the MAPKs, Ca2+/calmodulin-
dependent kinase II (CaMK-II) is a general integrator of Ca2+
signaling that has been linked to oncogene induction in several
cell lines [24,25]. The isoform CaMK-II is present in mesangial
cells [26,27]. Cadmium activates CaMK in cell-free systems
[28,29], although we previously reported that short-term treat-
ment of rat mesangial cells with Cd2+ did not activate CaMK-
II in these cell extracts [30].
CaMK-II has been linked to regulation of apoptosis. Hepa-
tocytes undergoing apoptosis following inhibition of protein
phosphatases were protected from DNA fragmentation and
polarized budding when CaMK-II inhibitors were added up
to 20 min after phosphatase inhibition [31], indicating a
CaMK-II-dependent commitment step at this time. The re-
lated kinases, CaMK-IV and CaMK-like kinase are both
cleaved by caspase-3 to facilitate neuronal apoptosis [32,33],
although CaMK is not consistently pro-apoptotic. Thus,
CaMK-IV inhibits apoptosis in neurons deprived of K+ [34].
Furthermore, CaMK-II maintains c-FLIP phosphorylation,
rendering apoptosis-resistant glioma cells proliferative in re-
sponse to Fas agonist, and over-expression of CaMK-II makes
sensitive cells resistant [35].
In the present study, we demonstrate that Cd2+ activates
CaMK-II in mouse mesangial cells and initiates both apoptotic
and necrotic cell death. Inhibition of CaMK-II increases cell
viability in the presence of Cd2+, primarily due to suppression
of apoptosis.2. Materials and methods
2.1. Cell culture
Mesangial cells were isolated from kidneys of 129/Sv mice using
Dynabeads as described [36], and characterized as homogeneous cul-
tures by morphology and staining for a-smooth muscle actin. Cells
were cultured in RPMI 1640 medium with 10% FBS and used between
passages 5 and 20. Before exposure to CdCl2, cells were rendered qui-
escent at 70–80% conﬂuence by growth in medium containing 0.2%
FBS for 48 h. Quiescent cells were then washed with PBS and pre-
treated with inhibitors in serum-free medium for 1 h before the addi-
tion of CdCl2 for up to 6 h. The inhibitors used (all from
CalBiochem, San Diego, CA) were KN93 (an inhibitor of the calmod-
ulin binding/activation site) and its inactive analogue KN92, KT5926
and K252a (competitive inhibitors of ATP binding at the catalytic
site), and myristoylated autocamtide-2-related inhibitory peptide
(AIP, a peptide analogue of the autoinhibitory domain of CaMK-II)
at concentrations of KN93/KN92 = 10 lM, KT5926 = 100 nM,blished by Elsevier B.V. All rights reserved.
Fig. 1. Activation of CaMK-II and Erk by Cd2+ in mesangial cells. (A)
Western blots of CaMK-II phosphorylated on Thr286 (pCaMK) and
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MMC by reversible permeabilization, as described previously [37].
Brieﬂy, starved cells were slowly cooled to 4 C by sequential 2-min
incubations with PBS. The cells were then incubated with freshly pre-
pared permeabilization buﬀer (20 mM HEPES, pH 7.4, with 10 mM
EGTA, 140 mM KCl, 50 lg/mL saponin, 5 mM NaN3, 6 mM ATP,
and 5 mM oxalic acid dipotassium salt) containing 100 lM myristoy-
lated-AIP for 20 min on ice. The cells were then gently washed four
times with chilled PBS. After a 20-min recovery on ice in PBS, the cells
were placed at room temperature for 2 min and then incubated in ser-
um-free medium at 37 C for 30 min before treatment with CdCl2.
2.2. Western blotting
Cells were lysed by two freeze–thaw cycles in 50 mM HEPES buﬀer
containing 0.5% Nonidet P-40, 1 mM Na3VO4, 25 mM NaF, 1 mM
PMSF, and 1 lg/ml each of aprotinin, leupeptin, and pepstatin. The
mixture was then sonicated twice for 5 s at 200 W and centrifuged
(15000 · g, 15 min). Cell extracts were separated by 10% SDS–poly-
acrylamide gel electrophoresis and transferred to nitrocellulose mem-
branes. Membranes were blocked with 5% BSA in TBS containing
0.1% Tween 20 and blotted overnight at 4 C with anti-phospho-
Thr286-CaMK-II (1:2000; BioSource, Camarillo, CA), anti-phospho-
Erk (1:2000; Cell Signaling, Beverly, MA), anti-Erk-2 cross-reactive
with both p42 and p44 Erk (1:2000; Santa Cruz Biotechnology, Santa
Cruz, CA), and anti-a-smooth muscle actin (1:5000, Sigma, St. Louis,
MO). Anti-CaMK-II-d2 was generously provided by Harold Singer
[38]. Signals were developed with horseradish peroxidase-conjugated
secondary Ab at room temperature for 60 min. Blots were washed
three times with TBS/Tween 20 and visualized with ECL Plus reagent
(Amersham, Baie d’Urfe´, PQ) according to the manufacturer’s instruc-
tions.
2.3. CaMK-II activity
Autonomous CaMK activity and total activity were measured as de-
scribed previously [27]. For autonomous activity, 5–10 lg of protein
were incubated at 30 C for 3 min in 25 ll of 50 mMHEPES assay buf-
fer containing 10 mM MgCl2, 0.1 mM ATP, 1 mM EGTA, 0.02 mM
autocamtide peptide (KKALRRQETVDAL) as substrate, and 5 lCi/
ml [c-32P] ATP. For total activity, EGTA was replaced by 4 mM CaCl2
and 2 lM calmodulin. Reaction was stopped by addition of ice-cold
TCA to 5%. The reaction mixture was spotted on P81 phosphocellu-
lose ﬁlters, washed with 75 mM H3PO4, and counted by liquid scintil-
lation.
2.4. Cell viability assay with thiazolyl blue (MTT)
Cells growing in 24-well plates were exposed to 1 mg/ml MTT in
200 ll phenol red-free RPMI 1640 for 1 h at 37 C. The medium was
removed, and 500 ll of DMSO was added with shaking for 30 min
at room temperature. Samples (100 ll) were placed in a 96-well plate,
and the absorbance read at 570 nm with background subtraction at
650 nm.
2.5. Detection of cell death by ﬂow cytometry
To detect phosphatidylserine externalization, 1 · 105 cells were sus-
pended in 100 ll binding buﬀer (10 mM Hepes/NaOH, pH 7.4,
140 mM NaCl, 2.5 mM CaCl2) containing 5 ll Annexin V-FITCTable 1
Cell viability by the MTT assay
Conditions Viability (%) Diﬀerence vs. Cd alone
Serum-free 79.5 ± 4.5 P < 0.001
Cd 28.7 ± 8.7 —
Cd + PD98059 27.6 ± 13.0 N.S.
Cd + KN93 45.0 ± 6.2 P < 0.05
Quiescent mouse mesangial cells were transferred to serum-free med-
ium with or without 15 lM CdCl2 for 6 h. The Erk inhibitor PD98059
(50 lM) or the CaMK-II inhibitor KN93 (10 lM) were included in
some cultures. Values are mean ± S.D. from six experiments and are
expressed as a percentage of the MTT absorbance in quiescent cultures
prior to transfer to serum-free conditions. All Cd2+ treatment groups
diﬀered from serum-free alone at P < 0.001.(BD Bioscience, Mississauga, ON) and 5 lg/ml propidium iodide (PI;
Sigma), and incubated for 15 min at room temperature. Then 400 ll
binding buﬀer was added and the samples were analyzed immediately
in an Epics Elite ﬂow cytometer (Beckman Coulter). Live cells were
considered to be Annexin V ve/PI ve; apoptotic cells Annexin V
+ve/PI ve, late apoptosis/necrosis Annexin V +ve/PI +ve.
2.6. Statistical analyses
Values are expressed as means ± S.D. and diﬀerences are evaluated
by ANOVA with post hoc testing by Dunnett’s test against control
(Table 1, Fig. 1C) or Tukey’s test for multiple within-group compari-
sons (Table 2).phosphorylated p42/p44 Erk (pErk) after treatment of mouse mesan-
gial cells with 10 lM CdCl2 for the times indicated. The blots are
typical of at least three independent experiments in each case. b-Actin
is immunoblotted on the same gels to serve as a loading control, and
total Erk and CaMK-II are also shown as evidence that gene
expression is not inﬂuenced. (B) Western blots of pCaMK and pErk
(as in panel A) in cell extracts from mesangial cells exposed for 6 h to
the indicated concentrations of Cd2+ as CdCl2. The blot is typical of at
least three experiments at most concentrations. (C) Measured CaMK
activity (total and autonomous using autocamtide as a substrate) in
extracts of mesangial cells that had been treated with 10 lM CdCl2 for
the times indicated. The results are representative of more than four
experiments with both mouse and rat mesangial cells. In the experi-
ment shown, autonomous activity was 17% of total activity at t = 0,
rising to 37% at t = 4–6 h, as is typical of strong activation [39].
Signiﬁcantly diﬀerent from t = 0, *(P < 0.05) and **(P < 0.01). A
biphasic time course of phosphorylation and activity is apparent in
panels A and C, respectively.
Table 2








Serum-free 83.0 ± 4.1 8.9 ± 3.9 7.4 ± 2.1
CdCl2 (10 lM) 67.7 ± 10.1 23.7 ± 6.4 7.5 ± 3.7
CdCl2 (10 lM) + KN93 74.9 ± 16.8 14.0 ± 10.6 9.5 ± 6.1
CdCl2 (20 lM)
a18.8 ± 9.1 b56.2 ± 8.4 20.1 ± 13.1
CdCl2 (20 lM) + KN93
a67.3 ± 9.2 b16.3 ± 4.9 15.0 ± 4.0
Values (mean ± S.D.) are compiled from three independent experi-
ments of the type shown in Fig. 3. Cells are scored a viable (Annexin V
ve/PI ve), apoptotic (Annexin V +ve/PI ve), or late apoptotic/
necrotic (Annexin V +ve/PI +ve). Values marked adiﬀer signiﬁcantly
from one another, as do those marked b(P < 0.003 in both cases). Cells
staining Annexin V ve/PI +ve were less than 2% in all experiments.
Fig. 2. Eﬀect of CaMK-II inhibitors on Cd2+-induced phosphoryla-
tion. (A) Western blots of phospho-CaMK-II and b-actin after
treatment of cells in serum-free conditions for 4 h with or without
10 lM CdCl2 in the presence or absence of KN93 or its inactive
analog, KN92. (B) Western blots of phospho-CaMK-II, phospho-Erk,
and b-actin after cells are held in serum-free (SF) conditions for 4 h or
6 h, or treated with 10 lM CdCl2 (Cd) or CdCl2 with the inhibitors
KT5926 (KT), K-252a or AIP. (C) Western blots of phospho-Erk and
the corresponding b-actin signal immediately below, after 1 h or 6 h
treatment with 10 lM CdCl2, KN93, or KN92, as indicated. All blots
are representative of at least three independent experiments except AIP
(tested twice).
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Activation of CaMK involves autophosphorylation trig-
gered by Ca2+/calmodulin. Time course experiments at
10 lM Cd2+ showed a biphasic increase in phosphorylation
of Thr286 of CaMK-II (phospho-CaMK-II) after 1 min and
again after 4–6 h (Fig. 1A). We examined the concentration
dependence of this activated form by Western blot at 6 h
(Fig. 1B). Concentrations of 3–20 lM Cd2+ (a concentration
range that activates MAPK signaling in mesangial cells
[22,23]) markedly increased phospho-CaMK-II. Higher con-
centrations caused a loss of signal. Concentrations of 10 lM
and higher also caused increased phosphorylation of Erk, as
reported before [22], but in contrast to phospho-CaMK, phos-
pho-Erk continued to increase even at 40 lM Cd2+ (Fig. 1B).
The time course of phosphorylation of Erk was also biphasic,
consistent with previous observations [22], with maxima lag-
ging behind those of phospho-CaMK-II. The autonomous
CaMK-II activity (Fig. 1C) corresponded to the pattern of
phosphorylation of Thr286, with an increase of approximately
2-fold at 5 min that declined, began to rise again at 2 h, and
reached 3-fold at 4–6 h. Total CaMK-II activity measured in
the presence of excess Ca2+ and calmodulin added to the assay
mixture was unchanged over 6 h of Cd2+ treatment.
Based on the time course in Fig. 1, we looked at the eﬀect of
CaMK-II inhibitors on CaMK-II phosphorylation at 4 h and
on Erk phosphorylation at 1 h and 6 h of Cd2+ treatment.
The inhibitor KN93 suppressed the Cd2+-dependent phos-
phorylation of CaMK-II, but the inactive analog KN92 did
not (Fig. 2A). Neither compound aﬀected CaMK-II phosphor-
ylation in the absence of Cd2+. Three other CaMK-II inhibi-
tors, KT5926, K-252a, and AIP also blocked activation by
Cd2+ (Fig. 2B). The CaMK-II-speciﬁc peptide analogue,
AIP, decreased CaMK-II phosphorylation by 40% in two sep-
arate experiments. The lower eﬃciency of inhibition by AIP is
likely due to peptide availability and the need for cell perme-
abilization for uptake. CaMK-II has been reported to signal
upstream of Erk in vascular smooth muscle, with c-Src and
the EGF receptor mediating ras/raf/MEK-dependent Erk
phosphorylation [37]. KN93, but not KN92, decreased Cd2+-
dependent Erk phosphorylation (Fig. 2C), indicating Erk
may also be a downstream target in the CaMK-II pathway
in mouse mesangial cells. However, KT5926, K252a, and
AIP did not decrease phospho-Erk levels (Fig. 2B), suggesting
additional non-speciﬁc eﬀects of KN93 on Erk.Because CaMK-II has been implicated in regulating apopto-
sis, we determined the eﬀect of Cd2+ and of CaMK-II inhibi-
tion on cell viability. For a 6 h exposure to 15 lM Cd2+, this
assay showed a decrease to 36 ± 11 % of the viability of ser-
um-free cells alone (28.7% compared to quiescent cells before
transfer to serum-free medium; Table 1). Inclusion of the
CaMK-II inhibitor KN93 during Cd2+ treatment partially
restored viability to 56 ± 7% of the serum-free value (n = 6,
P < 0.05 vs. Cd2+ alone), whereas the Erk inhibitor PD98095
was without any protective eﬀect, indicating that CaMK-II
partially mediates Cd2+-dependent cell death, and does so in
an Erk-independent manner. K525a and AIP, which do not af-
fect Erk phosphorylation, were also both protective of viability
in the MTT assay (data not shown). Flow cytometry (Fig. 3)
indicated that Cd2+ is killing the cells by both apoptotic (An-
nexin V +ve/PI ve) and late apoptotic/necrotic (Annexin V
+ve/PI +ve) pathways (see Section 4). KN93 and KT5926 pro-
tected cell viability, and did so markedly following a 6 h expo-
sure to 20 lMCd2+. This was in large part due to a decrease in
apoptosis (e.g., from 56 ± 8% of cells in 20 lM Cd2+ to
16 ± 5% when KN93 was included; Table 2).4. Discussion
CaMK-II is the major CaMK in mesangial [26,39] and other
smooth muscle [37,40] cells. It is activated upon binding of
Fig. 3. Flow cytometric analysis of cell death. Cells were stained with Annexin V-FITC and propidium iodide as described in Section 2 and subjected
to ﬂow cytometry. Relative ﬂuorescent intensity of the labels are indicated on the axes. Cells in the lower left quadrant of each panel are considered
negative for both label, i.e., they are viable. Cells in the lower right quadrant are apoptotic. In these experiments, control cells are compared with cells
treated for 6 h with 10 lM CdCl2, 20 lM CdCl2, or 20 lM CdCl2 with KN93 or KT5926. Note that gating and correction for autoﬂuorescence
(eﬀectively setting the axes for quadrant division) is optimized within each experiment, and each pair of horizontal images is matched from the same
experiment. Results of multiple analyses are compiled in Table 2.
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and then takes on autonomous activity independent of cal-
modulin binding [41]. By virtue of its similar ionic radius to
Ca2+, Cd2+ can bind to calmodulin in vitro with a Kd of
4.5 lM and activate it to bind phosphodiesterase [29,42].
KN93 acts at the calmodulin binding site of CaMK to prevent
binding, and suppression of Cd-dependent phosphorylation by
KN93 indicates that Cd2+ is activating calmodulin binding
in vivo. This is further conﬁrmed with inhibitors KT5926,
K252b, and AIP that act through diﬀerent mechanisms (see
Section 2), and a lack of eﬀect of the analogue KN92.We previously reported that Cd2+ did not increase total
CaMK-II activity in rat mesangial cells at 1 h of treatment
in serum-free medium, and at concentrations of 5 lM and
above actually inhibited autonomous activity measured
against autocamtide-2 peptide as substrate [30]. The lack of
activation at 1 h is consistent with the present study. However,
we show here that at both earlier and later times Cd2+ does
activate CaMK-II. The mechanism of this biphasic eﬀect is un-
known. As Cd2+ enters mesangial cells by diﬀusion, linearly
over a prolonged time period [43], the early activation of
CaMK-II at 1–5 min may be due to mobilization of Ca2+.
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to an orphan receptor on the cell surface [44]. However, we
were unable to demonstrate a Ca2+ signal in response to
Cd2+ in mesangial cells [45], and although this does not rule
out Ca2+ acting locally or at privileged sites, it leaves the mech-
anism of the ﬁrst phase of activation an open question. The
second phase of activation may occur when intracellular
Cd2+ levels are suﬃcient to activate calmodulin directly.
The prevention of CaMK-II Thr286 phosphorylation by the
four CaMK inhibitors is good evidence of a speciﬁc eﬀect of
Cd2+ acting through CaMK-II. Activation of Erk by CaMK-
II has been described in vascular smooth muscle cells, through
a pathway involving EGF receptor downstream of CaMK-II
[37]. However, in the present study, KT5926, K252a, and
AIP had no eﬀect on Erk, suggesting CaMK-II is not involved
in Cd2+-mediated Erk activation. The mechanism of suppres-
sion of Erk activation by KN93 is unknown, but is not due
to a non-speciﬁc inhibitory eﬀect of KN93 on the ras/raf/
MEK/Erk arm of the signal, because KN93 had no eﬀect on
phorbol ester-induced Erk phosphorylation (data not shown).
As apoptotic cells may take up PI in late apoptosis, the ﬂow
cytometric method used here cannot distinguish late apoptosis
from necrosis. However, the increase in the Annexin V +ve/PI
+ve population with time and increasing Cd2+ concentration
(data not shown, but compare 10 lM and 20 lM Cd in
Fig. 3) suggests that the early eﬀect of Cd2+ is primarily apop-
totic in mesangial cells under serum-free conditions. It is note-
worthy that inhibition of CaMK-II, but not of Erk, eﬀectively
suppresses apoptosis and increases viability of Cd2+-treated
cells in general, suggesting an apoptotic eﬀect of CaMK-II
independent of any role it may have in Erk signaling. Inhibi-
tion of phosphatases appears to lead to apoptosis through sus-
tained CaMK-II activity [31,46] and CaMK inhibitors
protected hepatocytes from DNA fragmentation after phos-
phatase inhibition [31]. The related kinases, CaMK-IV and
CaMK-like kinase are both cleaved by caspase-3 to facilitate
neuronal apoptosis [32,33]. However, CaMK is not consis-
tently pro-apoptotic. Thus, CaMK-IV inhibits apoptosis in
neurons deprived of K+ [34] and CaMK-II maintains c-FLIP
phosphorylation and renders Fas-sensitive glioma cells resis-
tant to apoptosis [35].
In summary, we have demonstrated activation of CaMK-II
by Cd2+ in intact mesangial cells, and implicated CaMK-II in
Cd2+-dependent apoptosis.
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